Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene Closes $97 Million Round to Develop Hematology/Oncology Portfolio

publication date: Jul 20, 2020

Shanghai Antengene closed a $97 million Series C financing to support its portfolio of 12 hematology and oncology drug candidates. Half of the portfolio has started clinical trials in China. Antengene in-licenses China rights to programs and conducts its own R&D on novel small molecules, monoclonal and bi-specific antibodies for cancer. The company said it would use the proceeds to fund clinical development of its pipeline, expand in-house R&D and build commercial infrastructure in APAC markets. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital